You are here
News
2026
Aug 2026 ReeLabs of India stores stem cells from six perinatal sources and four adult sources. ReeLabs is also at the forefront of the regenerative medicine revolution in India. They run clinical trials of cell therapies and offer a patented anti-aging treatment.
Aug 2026 The placenta is destined to be a temporary organ: when its time is up, a cascade of signals tells the mother's body to expel the placenta after birth. Safe delivery of the placenta is essential to prevent excessive bleeding after birth.
Jul 2026 Registration is now open for the AABB 2026 Annual Meeting, to be held Oct. 17-19 in Atlanta, Georgia, USA.
Jul 2026 Extremely premature babies require multiple blood transfusions for anemia. But they benefit more from cord blood than adult blood, because it is rich in fetal hemoglobin. This need could be met by processing the red blood cells that cord blood banks routinely discard, turning it into a product for the transfusion of premature babies.
Jul 2026 Neonatal cardiac surgery is one of the largest and most predictable clinical settings in which autologous cord blood can already be incorporated into routine care. When this indication is included, the odds of using cord blood nearly double. Family cord blood banks should make more effort to tell this story and provide this service.
Jul 2026 Interview with Rocio Ayala Edgerton of New England Cryogenic Center, about their partnership with Kindbody.
Jun 2026 We interview Nina Horowitz, PhD, the CEO of ImmuneBridge. Their technology can expand stem cells 100K-fold, making the large scale production of immunotherapy at affordable prices a possibility. They consider donated cord blood to be the ideal starting material for immunotherapy.
Jun 2026 China uses cord blood for about 500 pediatric stem cell transplants per year. This is more than Europe or North America.
Jun 2026 Post-Partum Depression occurs in up to 10% of Fathers. The rate is close to half of fathers when the mother is experiencing Post-Partum Depression.
May 2026 From Bank to Bedside is a series of profiles that describe organizations which offer consumers the full range of cellular therapy services, from biobanking to clinical medicine. This month we profile CHA of South Korea. CHA provides an integrated industry-academia-research-hospital ecosystem. The CHA Bio Group is one of the largest medical networks in the Asia-Pacific region, and aims to become the world leader in developing and commercializing new cell therapies.